LONA Stock Forecast: LeonaBio, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering LeonaBio, Inc. hold a median 12-month price target of $18 — +141.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 1 Aug 2026 — in the lower half.
LONA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores LeonaBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (16): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own LeonaBio, Inc. — and when they’d sell — is the membership.
LONA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LONA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +141.0% from it.
Of the 20 most recent actions, 0 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | Citizens | Upgrade | Market Outperform | $18 |
| 27 May 2026 | Piper Sandler | Initiates | Overweight | $20 |
| 27 May 2026 | Piper Sandler | Initiates | Overweight | — |
| 19 Feb 2026 | Mizuho | Upgrade | Outperform | — |
| 19 Sept 2024 | Mizuho | Downgrade | Neutral | $5.00 → $0.50 |
| 4 Sept 2024 | BTIG | Downgrade | Neutral | — |
| 4 Sept 2024 | JMP Securities | Downgrade | Market Perform | — |
| 19 Aug 2024 | Rodman & Renshaw | Initiates | Buy | $22 |
| 20 June 2024 | JMP Securities | Reiterates | Market Outperform | $19 |
| 16 May 2024 | JMP Securities | Reiterates | Market Outperform | $19 |
| 11 Aug 2023 | JMP Securities | Maintains | Outperform | $20 → $19 |
| 15 May 2023 | Mizuho | Maintains | Buy | $6.00 → $5.00 |
| 30 Mar 2023 | BTIG | Maintains | Buy | $33 → $10 |
| 24 Mar 2023 | JMP Securities | Reiterates | Market Outperform | $20 |
| 7 July 2022 | Mizuho | Initiates | Buy | $6.00 |
| 23 June 2022 | Jefferies | Downgrade | Hold | $32 → $3.00 |
| 23 June 2022 | JMP Securities | Downgrade | Market Perform | — |
| 23 June 2022 | Stifel | Downgrade | Hold | $36 → $5.00 |
| 10 May 2022 | BTIG | Initiates | Buy | — |
| 21 Apr 2022 | Berenberg | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LONA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
LeonaBio, Inc. (LONA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.3×
- Price / sales
- —
- Price / book
- 1.3×
- EV / EBITDA
- 0.0×
Cheaper than 78% of US stocks
Cheaper than 61% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −298.8%
- Return on assets
- −46.5%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
LONA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LONA appears on the weeks it earns a place.
Frequently asked questions about LONA stock
What is the LONA stock price forecast for 2026-2027?
The 4 Wall Street analysts covering LeonaBio, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LONA stock a buy right now?
Of the 4 analysts covering LeonaBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LeonaBio, Inc. 48 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LONA?
As at 1 Aug 2026, LeonaBio, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).
Will LONA stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +141.0% from the last close, and Ticker Nerd's factor model ranks LeonaBio, Inc. 48 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LONA stock forecast for 2030?
No analyst covering LeonaBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LONA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $20 over the next 12 months.
How has LONA stock performed over the past year?
LeonaBio, Inc. returned +101.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does LeonaBio, Inc. do?
Athira Pharma Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases.
About LeonaBio, Inc.
Athira Pharma Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company's primary aim is to discover and commercialize novel therapeutics targeting Alzheimer's disease and other neurological disorders. Athira Pharma's lead product candidate is designed to help repair neuronal damage, potentially offering a regenerative approach to these debilitating conditions. The company employs cutting-edge research in protein therapeutics and uses proprietary small molecule therapeutics to improve cognitive function by targeting mechanisms that facilitate neural health and maintenance. Based in the biopharmaceutical innovation hub of the United States, Athira Pharma plays a significant role in the biotech sector, particularly in the neurology and Alzheimer's treatment market. It operates within a crucial segment of the healthcare industry, addressing some of the most challenging and urgent unmet medical needs. The company's initiatives, driven by scientific research and development, underline its commitment to transforming the treatment landscape for neurodegenerative diseases, contributing to the broader goals of the healthcare and life sciences industries.
CEO Dr. Mark J. Litton M.B.A., Ph.D. · 19 employees · United States · https://www.leonabio.com